Most important new report today, and highly encouraging: Real world vaccine effectiveness (E) in >380,000 people in Qatar to B.1.1.7 (UK) and B.1.351 (South Africa) variants, *100% E vs severe illness both*👍 @NEJM
nejm.org/?query=feature…
nejm.org/?query=feature…
Text and Extended Table
1. One dose is not sufficient, especially B.1.351 which has a significant immune evasion property (most of all variants to date)
2. E vs infection of any type (PCR +) very solid 75% for B.1.351
1. One dose is not sufficient, especially B.1.351 which has a significant immune evasion property (most of all variants to date)
2. E vs infection of any type (PCR +) very solid 75% for B.1.351
Updating the evidence table for the essential point that we have vaccines that provide protection against all variants
Reposting the recent @nytopinion essay about having confidence in our ability to combat the major variants with vaccines and not mixing them up the multitude of scariants
nytimes.com/2021/04/13/opi…
nytimes.com/2021/04/13/opi…
Also published today is the @Novavax randomized trial data in South Africa, confirming 50% efficacy vs B.1.351 with genome sequencing nejm.org/doi/full/10.10…
(Now 3 effective vaccines, J&J, mRNA/Pfizer and Novavax vs the variant w/ highest level of immune evasion)
(Now 3 effective vaccines, J&J, mRNA/Pfizer and Novavax vs the variant w/ highest level of immune evasion)
Coverage on this good news by @EmilyAnthes
nytimes.com/live/2021/05/0… "incredibly effective"
Links also to report on the 40 participant study with the @Moderna booster vaccine against B.1.351 @apoorva_nyc
nytimes.com/live/2021/05/0… "incredibly effective"
Links also to report on the 40 participant study with the @Moderna booster vaccine against B.1.351 @apoorva_nyc
• • •
Missing some Tweet in this thread? You can try to
force a refresh
